低甲基化剂增加L1反元素表达,而不会诱导骨髓性恶性瘤的新插入
Šárka Pavlová1,2,3, Hana Svozilová1,2,3, Marcela Krzyžánková1
1Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
低甲基剂增加白血病细胞中的反元素蛋白表达,但即使长期暴露,也不会引起新的体质反转换事件. 这表明这些药物不会通过反向元素活动驱动疾病的进展.
科学领域:
- 基因组学
- 表观遗传学
- 癌症生物学
背景情况:
- 人类基因组含有反元素,
- 在瘤中观察到逆元素放松,但其在白血病中的作用尚不清楚.
- 低甲基剂用于治疗骨髓发育综合征和急性骨髓性白血病.
研究的目的:
- 调查低甲基剂是否会增加白血病中的反元素活性和体质反转移.
- 评估长期低甲基化剂治疗对骨髓性恶性瘤的反元素动态的影响.
主要方法:
- 在骨髓细胞系中使用低甲基化剂诱导ORF1p蛋白表达 (DAMI,HL-60).
- 对治疗4周的细胞系进行分析.
- 根据下一代测序 (NGS) 来分析接受低甲基化剂治疗的17名骨髓发育综合征患者的测序样本.
主要成果:
- 低甲基剂成功诱导了骨髓细胞系中LINE-1编码蛋白 (ORF1p) 的表达.
- 在长期暴露于低甲基化剂后,在细胞系或患者样本中没有检测到新的体内逆转换事件.
- 敏感的NGS方法证实没有反元素活动.
结论:
- 虽然低甲基化剂会激活骨髓细胞中的反元素蛋白表达,但它们似乎不会诱导新的体质逆转换事件.
- 在白血病中长期暴露于低甲基化剂不会导致反元素活性增加.
- 这些发现表明,在骨髓癌治疗期间,反元素活性可能不是疾病进展的重要因素.
更多相关视频
13:47Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution
Published on: February 24, 2015
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
相关概念视频
Non-LTR Retrotransposons
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
